[1]李静虹,刘红莲,宗凯仁,等.含贝达喹啉全口服短程化疗治疗耐多药肺结核疗效及安全性观察临床研究[J].陕西医学杂志,2024,(7):958-961.[doi:DOI:10.3969/j.issn.1000-7377.2024.07.020]
　LI Jinghong,LIU Honglian,ZONG Kairen,et al.Efficacy and safety of total oral short-course chemotherapy containing Bedaquinoline in treatment of patients with multidrug resistant pulmonary tuberculosis[J].,2024,(7):958-961.[doi:DOI:10.3969/j.issn.1000-7377.2024.07.020]
点击复制

含贝达喹啉全口服短程化疗治疗耐多药肺结核疗效及安全性观察临床研究
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
期数:
2024年7期
页码:
958-961
栏目:
药物与临床
出版日期:
2024-07-05

文章信息/Info

Title:
Efficacy and safety of total oral short-course chemotherapy containing Bedaquinoline in treatment of patients with multidrug resistant pulmonary tuberculosis
作者:
李静虹1;  刘红莲2;  宗凯仁3;  周燕红4;  钟 诚3
(1.江西省胸科医院感染性疾病科,江西 南昌 330006; 2.江西省胸科医院科教科,江西 南昌 330006; 3.江西省胸科医院结核二科,江西 南昌 330006; 4.江西省胸科医院结核病综合防治科,江西 南昌 330006)
Author(s):
LI Jinghong; LIU Honglian; ZONG Kairen; ZHOU Yanhong; ZHONG Cheng
(Department of Infectious Diseases,Jiangxi Provincial Chest Hospital,Nanchang 330006,China)
关键词:
耐多药肺结核;  贝达喹啉;  短程化疗;  疗效;  不良反应;  安全性
Keywords:
Multidrug-resistant tuberculosis;  Bedaquinoline;  Short-course chemotherapy;  Curative effect;  Adverse reactions;  Security
分类号:
R 521
DOI:
DOI:10.3969/j.issn.1000-7377.2024.07.020
文献标志码:
A
摘要:
目的:探讨含贝达喹啉全口服短程化疗治疗耐多药肺结核患者的疗效及安全性。方法:选择100例耐多药肺结核患者,以随机数字表法将其分为对照组(WHO长疗程方案)50例和观察组(含贝达喹啉全口服短程方案)50例。比较两组患者痰培养阴转率、治愈率,并行胸部CT检查,观察病灶及空洞变化,并记录不良反应率发生情况。结果:观察组24周阴转率为84.00%(41/50)高于对照组74.00%(27/50),观察组36周时病灶吸收及空洞改善好于对照组(P<0.05)。观察组终点治愈率76.00%(38/50)高于对照组治愈率52.00%(26/50)(P<0.05)。对照组治疗过程中共出现不良反应84例次,观察组共出现不良反应69例次,两组不良反应发生情况比较,差异有统计学意义(P<0.05)。结论:含贝达喹啉全口服短程化疗方案治疗耐多药肺结核疗程短、治愈率高、安全性良好。
Abstract:
Objective:To investigate the efficacy and safety of total oral short-course chemotherapy containing Bedaquinoline in the treatment of multi-drug resistant pulmonary tuberculosis.Methods:A total of 100 patients with MDR-TB were selected and divided into control group(WHO long-course regimen,50 cases)and observation group(including Bedaquinoline short-course regimen,50 cases)by random number table method.The negative conversion rate and cure rate of sputum culture were compared between two group,and the changes of lesions and cavities were observed by chest CT,and the occurrence rate of adverse reactions was recorded.Results:The negative conversion rate at 24 weeks in the observation group was 84.00%(41/50),higher than 74.00%(27/50)in the control group.The improvement of lesion absorption and cavity in the observation group at 36 weeks was better than that in the control group(P<0.05).The cure rate of observation group was 76.00%(38/50),higher than 52.00%(26/50)of control group(P<0.05).There were a total of 84 adverse reactions in the control group and 69 adverse reactions in the observation group.There was statistical significance in the occurrence of adverse reactions between the two groups(P<0.05).Conclusion:Total oral short-course chemotherapy containing Bedaquinoline has short course of treatment,high cure and good safety.

参考文献/References:

[1] DALEY C L,CAMINERO J A.Management of multidrug-resistant tuberculosis[J].Semin Respir Crit Care Med,2018,39(3):310-324.
[2] 甘昭平,梁亚萍,赵涛,等.等位基因多重PCR技术快速诊断耐药结核病的应用研究[J].陕西医学杂志,2018,47(11):1438-1440,1444.
[3] 李晓晓,梁亚萍,赵涛,等.结核病患者422例耐药情况调查研究[J].陕西医学杂志,2020,49(2):250-253.
[4] 张琦.结核丸联合西药治疗耐多药肺结核的疗效观察[J].陕西中医,2016,37(4):434-435.
[5] HARGREAVES S,LÖNNROTH K,NELLUMS L B,et al.Multidrug-resistant tuberculosis and migration to Europe[J].Clin Microbiol Infect,2017,23(3):141-146.
[6] MARTÍN-GARCÍA M,ESTEBAN J.Evaluating bedaquiline as a treatment option for multidrug-resistant tuberculosis[J].Expert Opin Pharmacother,2021,22(5):535-541.
[7] 丁杨明,陆宇.抗耐药结核新药贝达喹啉、德拉马尼和普托马尼的药动学特征及药物相互作用研究进展[J].中国抗生素杂志,2023,48(3):351-356.
[8] 中华医学会结核病学分会.中国耐多药和利福平耐药结核病治疗专家共识(2019年版)[J].中华结核和呼吸杂志,2019,42(10):733-749.
[9] 袁平,杨铭,吴桂辉,等.贝达喹啉治疗耐多药、广泛耐药肺结核患者的疗效和安全性观察[J].四川医学,2022,43(6):588-592.
[10] 阳曼丽,周桂智.生脉饮联合黄芪注射液辅助治疗耐药肺结核的疗效评价[J].陕西中医,2016,37(11):1472-1474.
[11] 周燕,周萌,彭军,等.耐多药肺结核家庭内传播情况分析[J].中国防痨杂志,2023,45(2):195-199.
[12] 潘辰慧,张顺先,张少言,等.耐多药肺结核治疗转归的影响因素分析[J].解放军医学杂志,2023,48(9):1040-1047.
[13] LI Y,SUN F,ZHANG W.Bedaquiline and delamanid in the treatment of multidrug-resistant tuberculosis:Promising but challenging[J].Drug Dev Res,2019,80(1):98-105.
[14] KHAN U,HUERGA H,KHAN A J,et al.The end TB observational study protocol:treatment of MDR-TB with bedaquiline or delamanid containing regimens[J].BMC Infect Dis,2019,19(1):733.
[15] 杨松,王乐乐,韩梅,等.世界卫生组织耐药结核病治疗整合指南(2020年版)解读[J].国际呼吸杂志,2021,41(6):401-409.
[16] 裴异,陈检才,封文军,等.含贝达喹啉方案治疗耐多药/广泛耐药结核病中期疗效前瞻性队列研究[J].中国感染控制杂志,2021,20(12):1102-1108.
[17] 吴桂辉,邹莉萍,梁丽,等.含贝达喹啉及利奈唑胺方案治疗耐多药结核病视神经病变的发生及危险因素分析[J].临床肺科杂志,2023,28(4):505-510.
[18] GAO M Q,GAO J T,XIE L,et al.Early outcome and safety of bedaquiline-containing regimens for treatment of MDR-and XDRTB in China:A multicentre study[J].Clin Microbiol Infect,2021,27(4):597-602.
[19] 丁杨明,陆宇.抗耐药结核新药贝达喹啉、德拉马尼和普托马尼的药动学特征及药物相互作用研究进展[J].中国抗生素杂志,2023,48(3):351-356.
[20] 谢莉,朱慧,高静韬,等.贝达喹啉血药浓度在耐药肺结核治疗中的变化及其与QTc间期延长的相关性[J].中国防痨杂志,2022,44(3):219-226.
[21] 周安琴,罗敏,张登亮,等.盐酸莫西沙星注射液与注射用盐酸胺碘酮联用致QT间期延长[J].药物不良反应杂志,2020,22(1):42-43.
[22] 药飞,王东晓.临床药师在莫西沙星致QT间期延长不良事件中的实践[J].中国药物应用与监测,2020,17(2):96-99.
[23] 金龙,王利华,张晓磊,等.改良全口服短程化疗方案治疗耐多药肺结核的有效性及安全性分析[J].中国防痨杂志,2022,44(12):1321-1326.
[24] 梁丽,邹莉萍,袁平,等.贝达喹啉与其他致QT间期延长药物联合应用对耐多药肺结核患者QT间期的影响[J].中国感染与化疗杂志,2022,22(5):563-569.

备注/Memo

备注/Memo:
基金项目:中央引导地方科技发展基金资助项目(20221ZDG020069); 江西省应用研究培育计划项目(20212BAG70015)
更新日期/Last Update: 2024-07-04